deltatrials
Completed INTERVENTIONAL NCT02149589

Lung Imaging for Ventilatory Setting in ARDS

Sponsor: AZUREA group

Conditions ARDS
Updated 8 times since 2017 Last updated: Apr 16, 2026 Started: Jun 1, 2014 Primary completion: Jun 12, 2017 Completion: Feb 2, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02149589, this observational or N/A phase trial focuses on ARDS and remains completed. Sponsored by AZUREA group, it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Study Description(click to expand)

Early ARDS, less than 12 hours will be included. After Lung imaging, they will be randomized to a control group (PEEP/FiO2 according to ARDSnetwork tables) or an intervention arm. In this arm, mechanical ventilation will be set according to lung morphology. In patients with focal ARDS, prone position will be start quickly for at least 16 hours. After, A low PEEP and 8ml/kg of PBWwill be used. In non-focal ARDS, a recruitment maneuver followed by a high PEEP and a small tidal volume strategy will be used. In both arms, patients will be sedated and paralyzed during maximum 48 hours. As soon as PaO2/FiO2 \> 200 mmHG, myorelaxant and sedation will be withdrawal. Pressure support ventilation will be used as soon as possible and weaning from ventilation will be checked everyday

Early ARDS, less than 12 hours will be included. After Lung imaging, they will be randomized to a control group (PEEP/FiO2 according to ARDSnetwork tables) or an intervention arm. In this arm, mechanical ventilation will be set according to lung morphology. In patients with focal ARDS, prone position will be start quickly for at least 16 hours. After, A low PEEP and 8ml/kg of PBWwill be used. In non-focal ARDS, a recruitment maneuver followed by a high PEEP and a small tidal volume strategy will be used. In both arms, patients will be sedated and paralyzed during maximum 48 hours. As soon as PaO2/FiO2 \> 200 mmHG, myorelaxant and sedation will be withdrawal. Pressure support ventilation will be used as soon as possible and weaning from ventilation will be checked everyday

Status Flow

~Jan 2017 – ~Jul 2017 · 6 months · monthly snapshotRecruiting~Jul 2017 – ~Mar 2018 · 8 months · monthly snapshotUnknown Status~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Apr 2026 · 20 months · monthly snapshotCompletedApr 21, 2026 – present · 4 months · daily APICompleted

Change History

8 versions recorded
  1. Apr 21, 2026 — Present [daily]

    Completed

    Phase: NANone

  2. Sep 2024 — Apr 2026 [monthly]

    Completed NA

  3. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  4. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  5. Jun 2018 — Jan 2021 [monthly]

    Completed NA

Show 3 earlier versions
  1. Mar 2018 — Jun 2018 [monthly]

    Completed NA

    Status: Unknown StatusCompleted

  2. Jul 2017 — Mar 2018 [monthly]

    Unknown Status NA

    Status: RecruitingUnknown Status

  3. Jan 2017 — Jul 2017 [monthly]

    Recruiting NA

    First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

To compare in ARDS patients 2 ventilatory Strategies : One based on Lung Morphology (Focal versus non-Focal ARDS) versus ARDS networks Guidelines (PEEP based on FiO2). In Focal ARDS prone position will be promote early, with low PEEP and moderate Vt. In non-Focal ARDS, Recruitment maneuvers, high PEEP and low V twill be used. The investigators made the hypothesis that ventilation according to Lung morphology my decrease mortality at D90.

Contact Information

Sponsor contact:
  • AZUREA group
  • University Hospital, Clermont-Ferrand
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations